Sage Therapeutics (SAGE) PT Raised to $103 at Goldman Sachs, Says Co. Is Attractive Acquisition Target
Tweet Send to a Friend
Goldman Sachs raised its price target on Sage Therapeutics (NASDAQ: SAGE) to $103.00 (from $65.00) while maintaining a Buy rating.Analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
